Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation
about
Clonal hematopoiesis in acquired aplastic anemiaEltrombopag in aplastic anemiaIncreased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure.Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.Rare cytogenetic abnormalities in myelodysplastic syndromes.Clonal evolution and clinical significance of copy number neutral loss of heterozygosity of chromosome arm 6p in acquired aplastic anemiaComment to "Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation" Haematologica. 2012;97(12):1845-9.Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.Clinical significance of acquired somatic mutations in aplastic anaemia.Aplastic anemia and clonal evolution: germ line and somatic genetics.Recent advances in understanding clonal haematopoiesis in aplastic anaemia.Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated?
P2860
Q28079733-27A6FC24-7996-42A8-A563-0CFCA20D91F5Q28085299-DBBD6725-C0FB-44DF-B515-73BD804B9A0DQ33405829-F4E304D9-43FE-4C24-8337-EDE593371655Q33428604-A5C742FD-B00A-4190-AC6F-A888097C9F55Q34392449-372F1BFD-5900-4445-93C9-D0DE3ADFFA0EQ35252614-1D8DA335-5771-42ED-A5BF-A34B6D2CB7E5Q35565387-0698F86C-AE73-48DC-A12D-6952BB837BB6Q36535499-E63933D9-4E57-4FB8-AD58-68C711526055Q36862562-E9C7B56D-4135-4539-86C0-5EC0D863A9CDQ37730037-4E3FFBF2-309A-4751-81A9-A4908A99D6B3Q38809618-CEA05450-3359-4E1C-8B45-CDF86C5BC850Q39027706-E4BA1552-27CA-43AF-807B-018F25F9DCBDQ39096716-C148D7A6-AC0E-47A9-9B1B-DD5CEC6CC887Q54043084-8047B872-B13F-4E58-B8A3-7E40A826C4AD
P2860
Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Favorable outcome of patients ...... of the WHO 'MDS-U' designation
@ast
Favorable outcome of patients ...... of the WHO 'MDS-U' designation
@en
type
label
Favorable outcome of patients ...... of the WHO 'MDS-U' designation
@ast
Favorable outcome of patients ...... of the WHO 'MDS-U' designation
@en
prefLabel
Favorable outcome of patients ...... of the WHO 'MDS-U' designation
@ast
Favorable outcome of patients ...... of the WHO 'MDS-U' designation
@en
P2093
P2860
P1433
P1476
Favorable outcome of patients ...... of the WHO 'MDS-U' designation
@en
P2093
Aiko Sato-Otsubo
Ken Ishiyama
Masashi Sanada
Naomi Sugimori
Seishi Ogawa
Shinji Nakao
Takamasa Katagiri
Yumi Sasaki
P2860
P304
P356
10.3324/HAEMATOL.2011.061127
P577
2012-06-11T00:00:00Z